Dealmaking for Life Sciences Issuers in the COVID-19 World
Date: May 12, 2020
Time: 1:00PM - 2:00PM (EST)
Location: View the Webinar Recording
The COVID-19 global pandemic has fundamentally altered how equity financing and M&A transactions are being structured by and for life sciences issuers.
Join this panel of life sciences industry experts, from investment bankers and advisers to equity capital market participants and companies exploring M&A transactions, to learn about what trends and opportunities they see as the “new normal” continues to evolve.
Megan N. Gates
Megan N. Gates is a Mintz corporate and securities attorney who guides public companies through capital-raising transactions, SEC reporting obligations, and mergers and acquisitions. She advises clients on corporate governance and SEC compliance matters in the life sciences and other industries.
John T. Rudy
John T. Rudy is a Mintz Member who represents clients in capital markets transactions, securities, equity debt financings, and mergers and acquisitions. John's clients include public and private companies and investment banks. Before joining Mintz, he was an associate in a New York law firm.
Marc D. Mantell
Marc D. Mantell handles corporate and securities law matters at Mintz, primarily for technology clients. He represents companies, investors, underwriters, and other parties in mergers and acquisitions, securities offerings, debt financings, and other transactions.
Managing Director, Houlihan Lokey
Managing Director, Consilium Partners
Managing Director, Head of Biotechnology & Specialty Pharmaceuticals (US), Canaccord Genuity